Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Shares outstanding changed +15.0% from the comparable as-filed period. The change ranks at the 38th percentile of 8 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Current ratio changed -35.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Free-cash-flow margin changed +308 basis points from the comparable as-filed period.
R&D / revenue changed -908 basis points from the comparable as-filed period.
Receivables / revenue changed -2270 basis points from the comparable as-filed period.
Operating cash-flow margin changed +259 basis points from the comparable as-filed period.
Current liabilities changed +12.5% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Research & development changed -11.2% from the comparable as-filed period.
Capital expenditure changed -25.4% from the comparable as-filed period.
Trade receivables changed -9.7% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Capex / revenue changed -48 basis points from the comparable as-filed period.
Revenue changed +4.3% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Gross margin changed +43 basis points from the comparable as-filed period.
Research & development changed +6.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Inventory changed -4.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Capex / revenue changed +3 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Capital expenditure changed +7.3% from the comparable as-filed period. The change ranks at the 0th percentile of 6 prior comparable changes. This reverses 5 consecutive comparable moves in the opposite direction.
Gross profit changed +5.8% from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.